Industry News

Shire plc has been notified of an unsolicited "mini-tender" offer made by TRC Capital Corporation to purchase up to 1,000,000 American Depositary Shares of Shire, each representing three ordinary shares of Shire, at a price of $182.75 per ADS in cash. The offer is for approximately 0.33 percent of the outstanding ordinary shares of Shire."/>
Shire Recommends ADS Holders Reject TRC Capital's “Mini-Tender Offer”
Galapagos NV received a transparency notification from Federated Equity Management Company of Pennsylvania.. Pursuant to Belgian transparency legislation, Galapagos received a transparency notification on 26 July 2016 from Federated Investors, Inc. and Federated Equity Management Company of Pennsylvania, who notified that funds managed by Federated Equity Management hold 2,289,479 shares of the 46,109,508 currently outstanding..."/>
Galapagos receives transparency notification from Federated
Tokai Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, today announced that it is reducing its workforce by approximately 60 percent, to a total of 10 full-time equivalent employees, under a plan expected to be largely completed by the end of the third quarter of 2016. This workforce reduction is designed to reduce operating expenses while the..."/>
Tokai Pharmaceuticals Announces Reduction in Force
Exact Sciences Corp. today announced that, in support of the Company's continued growth plans, it granted restricted stock units covering a total of 214,035 shares of common stock to 58 recently hired employees under its previously announced inducement grant program. The restricted stock unit awards vest in four equal annual installments beginning on the first anniversary of the grant date. The awards were approved by the independent..."/>
Exact Sciences Grants Inducement Restricted Stock Unit Awards to Recently Hired Employees
Helix BioPharma Corp., an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for aggregate gross proceeds of approximately CAD1.8 million. The terms of the placement are for the purchase of units at $1.46 per unit. Each unit is comprised of one common share and one common share purchase warrant."/>
Helix BioPharma Corp. Closes CAD1.8 Million Private Placement
Natera, Inc.,, a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, applauds the new guidelines just released by the American College of Medical Genetics and Genomics, supporting the use of non-invasive prenatal tests as an optimal, initial option to screen for specific genetic conditions, such as Trisomy 21 during pregnancy. ACMG is the most recent medical society to advocate for broader adoption of..."/>
Statement from the American College of Medical Genetics and Genomics Supports the Use of Non-Invasive Prenatal Testing for All Pregnant Women
Ocular Therapeutix, Inc. concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors. Ocular is a biopharmaceutical company that focuses on the development and commercialization of therapies for diseases and conditions of the eye by using its proprietary hydrogel platform technology."/>
Glancy Prongay & Murray Commences Investigation on Behalf of Ocular Therapeutix, Inc. Investors
Evoke Pharma, Inc., today announced that it has entered into definitive agreements with institutional investors for an offering of shares of common stock with gross proceeds of approximately $10 million in a registered direct offering priced at the market price. The closing of the offering is expected to take place on or about August 3, 2016, subject to the satisfaction of customary closing conditions.. In connection with the offering, the..."/>
Evoke Pharma Announces $10 Million Registered Direct Offering Priced At-The-Market
SteadyMed Ltd., a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that it has entered into definitive agreements to sell shares of its common stock and warrants to purchase shares of its common stock for aggregate gross proceeds of up to approximately $32 million in a two-tranche private placement."/>
SteadyMed Raises up to $32 Million in Private Placement
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce they will release an inhalation medication for those suffering asthma/COPD for use in patient nebulizers. This product will be offered in states where marijuana is legal on a national basis. Based on State by State laws the Company can proceed with studies in the 25+ states approved for medical marijuana, and lay the groundwork for..."/>
Cannabis Science Develops Inhalation Medication for Those Suffering Asthma/COPD via Nebulizer, Targets National Markets
Neovasc Inc. securities between January 26, 2016 and May 19, 2016, inclusive. Neovasc investors have until August 5, 2016 to file a lead plaintiff motion. Investors suffering losses on their Neovasc investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to..."/>
Glancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Neovasc Inc. Investors and Encourages Investors to Contact the Firm
Sunshine Heart, Inc. announced today that its second quarter 2016 results will be released on Tuesday, August 9, 2016, before the open of the stock market. The company will host a conference call and webcast at 9:00 AM ET that morning, during which management will discuss the company’ s financial results and provide a general business overview.. To access the live webcast, please visit the Investors page of the Sunshine Heart website at..."/>
Sunshine Heart to Announce Second Quarter 2016 Results on August 9, 2016
Ensign Group, Inc., the parent company of the Ensign (TM) group of skilled nursing, rehabilitative care services, assisted living, home health and hospice care and urgent care companies, announced today that it expects to issue its second quarter 2016 financial results on Monday, August 1, 2016.. Ensign invites current and prospective investors to tune into a live webcast to be held the following day, Tuesday, August 2, 2016, at 10:00 a.m...."/>
The Ensign Group Schedules Second Quarter 2016 Earnings Call for Tuesday, August 2, 2016
Cigna will continue to work with its would-be buyer Anthem as the companies seek to convince a federal judge and regulators that their merged insurance giant would not be detrimental to consumers. The CEO of Bloomfield-based Cigna, David Cordani, told analysts during an earnings call Friday that it is "clearly our intent and commitment" to continue contributing significant time and resources to work on finalizing the $54 billion acquisition by Indianapolis-based..."/>
Cigna Committed To Fighting Antitrust Lawsuit, But Keeps Options Open [The Hartford Courant]
Emergent BioSolutions, Inc.. Investors who purchased or otherwise acquired shares between January 11, 2016 and June 21, 2016 are encouraged to contact the Firm in advance of the September 19, 2016 lead plaintiff motion deadline.. If you are a shareholder who suffered a loss during the Class Period, click here to participate."/>
SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Emergent BioSolutions, Inc. and Encourages Investors with Losses to Contact the Firm
ImpediMed Limited a global provider of medical technology to measure, monitor and manage fluid status and body composition, announced that Managing Director and CEO, Richard Carreon, presented at the Bioshares Biotech Summit 2016 in Queenstown, New Zealand, on Friday, July 29, 2016.. The topic for the presentation was "Opportunities for Digital Health Solutions." The presentation included details of ImpediMed's..."/>
ImpediMed Presents at Bioshares Biotech Summit 2016
Agilent Technologies Inc. will release third-quarter fiscal 2016 financial results after the stock market closes on Aug. 17. The company will host a live webcast of its investor conference call in listen-only mode. Date: Wednesday, Aug. 17, 2016 Time: 1:30 p.m. PDT Web access:"/>
Agilent Technologies to Host Webcast of Third-Quarter Fiscal Year 2016 Financial Results Conference Call
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that it has filed an international patent application with the US Patent& Trademark Office that covers transdermal extended-release formulations of clobazam, relating to the Company's AQS1302 program. This is the conversion of a provisional application which was filed on August 17, 2015. Aequus owns the..."/>
Aequus Announces Advancement of Clobazam Transdermal Patent Application
Ajanta Pharma Ltd on Friday said it has got approval from the US Food and Drug Administration to launch an oral suspension of omeprazole and sodium bicarbonate powder in the US market. Omeprazole and sodium bicarbonate is a bio-equivalent generic version of Zegerid, marketed by Bayer AG in the US. Ajanta said it will be launching the product soon in 2 strengths--20 mg/1680 mg and 40 mg/1680 mg sachets."/>
BRIEF: Ajanta Pharma gets USFDA nod to launch heartburn combination drug [Mint, New Delhi]
Adani Transmission Ltd became the third Indian company to issue dollar bonds this month, encouraged by the rally in bond markets across geographies. The firm raised $500 million at a coupon rate of 4%. ATL priced its dollar bonds at 260 basis points over the corresponding US Treasury note, lower than the indicative pricing of 290 bps above the US bond yield, according to two bankers associated with the deal."/>
Adani arm third company to issue dollar bonds amid global bond rally [Mint, New Delhi]
Cardiome Pharma Corp. announced today that it has closed its previously announced underwritten public offering of 11,500,000 common shares from treasury, including the underwriters' full exercise of their option to purchase 1,500,000 additional shares, at a price to the public of US $3.00 per common share, for aggregate gross proceeds to the Company of US $34,500,000, before deducting the underwriting commission and estimated Offering..."/>
Cardiome Closes Public Offering of 11,500,000 Common Shares
Cardiome Pharma Corp. announced today that it has closed its previously announced underwritten public offering of 11,500,000 common shares from treasury, including the underwriters' full exercise of their option to purchase 1,500,000 additional shares, at a price to the public of US $3.00 per common share, for aggregate gross proceeds to the Company of US $34,500,000, before deducting the underwriting commission and estimated..."/>
Cardiome Closes Public Offering of 11,500,000 Common Shares

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials941 Articles
Information Technology897 Articles
Consumer Discretionary757 Articles
Industrials597 Articles
Health Care592 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at